Seeking Alpha

Merck and Endocyte cancer products get thumbs up from EU committee

  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issues a positive opinion for Conditional Marketing Authorizations for VYNFINIT (vintafolide), FOLCEPRI (etarfolatide) and NEOCEPRI (intravenous folic acid) for the treatment of adult patients with folate receptor-positive platinum-resistant ovarian cancer.
  • The European Commission (EC) usually issues a legally binding decision within 3 months of a CHMP opinion. EC approval grants a centralized marketing authorization that is valid in the 28 members of the EU.
  • If approved, this will be the first oncology therapeutic to employ an imaging agent as a companion diagnostic for patient selection.
  • The products were developed by Endocyte (ECYT) but will be commercialized ex-US by Merck (MRK). The partners signed a $1B collaboration deal in 2012.
Comments (4)
  • TruffelPig
    , contributor
    Comments (4054) | Send Message
     
    Oh happy days are here :).
    21 Mar, 09:13 AM Reply Like
  • billy jones
    , contributor
    Comments (14) | Send Message
     
    Then why did the stick go down 5% Friday?
    23 Mar, 07:46 AM Reply Like
  • billy jones
    , contributor
    Comments (14) | Send Message
     
    So how come the stock fell about 5%?
    23 Mar, 08:12 AM Reply Like
  • TruffelPig
    , contributor
    Comments (4054) | Send Message
     
    $ECYT went up 92% on Friday. $Mrk 1.4% down. I have no clue what you are looking at Billy Jones.
    23 Mar, 02:25 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|